Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Could Clinical Profile Influence CSF Biomarkers in Early-onset Alzheimer Disease?
    Koric, Lejla
    Felician, Olivier
    Guedj, Eric
    Hubert, Anne Michele
    Mancini, Julien
    Boucraut, Jose
    Ceccaldi, Mathieu
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2010, 24 (03): : 278 - 283
  • [42] CSF biomarkers in Alzheimer's disease (AD): Changes with CSF drainage
    Silverberg, G
    Saul, T
    McGuire, D
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S382 - S382
  • [43] Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Blennow, Kaj
    Zetterberg, Henrik
    Minthon, Lennart
    Lannfelt, Lars
    Strid, Stig
    Annas, Peter
    Basun, Hans
    Andreasen, Niels
    NEUROSCIENCE LETTERS, 2007, 419 (01) : 18 - 22
  • [44] Proteomic discovery of CSF biomarkers for Alzheimer's disease
    Zhang, Jing
    Montine, Thomas J.
    ANNALS OF NEUROLOGY, 2007, 61 (05) : 497 - 497
  • [45] Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease
    Seppala, Toni T.
    Koivisto, Anne M.
    Hartikainen, Paivi
    Helisalmi, Seppo
    Soininen, Hilkka
    Herukka, Sanna-Kaisa
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (04) : 583 - 594
  • [46] CSF α-synuclein aggregation is associated with APOE ε4 and progressive cognitive decline in Alzheimer's disease
    Qiang, Qiang
    Skudder-Hill, Loren
    Toyota, Tomoko
    Huang, Zhe
    Wei, Wenshi
    Adachi, Hiroaki
    NEUROBIOLOGY OF AGING, 2025, 150 : 9 - 18
  • [47] Cognitive Impairment Associated with APOE Biomarkers in Alzheimer's Disease
    Diah, K.
    Vitale, G.
    Keith, M.
    Fornalski, N.
    Golden, C.
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2017, 32 (06) : 668 - 668
  • [48] CSF biomarkers in Alzheimer's disease - use in clinical diagnosis and to monitor treatment effects
    Blennow, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S159 - S159
  • [49] An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
    Van Hulle, Carol
    Jonaitis, Erin M.
    Betthauser, Tobey J.
    Batrla, Richard
    Wild, Norbert
    Kollmorgen, Gwendlyn
    Andreasson, Ulf
    Okonkwo, Ozioma
    Bendlin, Barbara B.
    Asthana, Sanjay
    Carlsson, Cynthia M.
    Johnson, Sterling C.
    Zetterberg, Henrik
    Blennow, Kaj
    ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 431 - 445
  • [50] Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF
    Canevelli, Marco
    Bacigalupo, Ilaria
    Gervasi, Giuseppe
    Lacorte, Eleonora
    Massari, Marco
    Mayer, Flavia
    Vanacore, Nicola
    Cesari, Matteo
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11